InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline

By Marketwired .

Article Rating:

June 3, 2015 06:00 AM EDT


VANCOUVER, BRITISH COLUMBIA — (Marketwired) — 06/03/15 — InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN)(OTCQB: IMLFF), a clinical halting-place biopharmaceutical company that specializes in developing safer, greater degree of effective cannabis-based therapies, announced it has initiated a program to prove to be identical and evaluate cannabinoid compounds for the treatment of chronic obstructive pulmonary disease (COPD). Initial medicine discovery and preclinical development is commonly underway in collaboration with members of the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia.

Craig Schneider, President & Chief Executive Officer, fixed, “We’re excited to explore avenues to further expand InMed’s pipeline with the joining of new program targeting COPD, the third leading cause of death in the United States. Similar to our ongoing program in orofacial anxiety, we are leveraging our proprietary astute drug design platform technology to take for identical promising therapeutic candidates. In addition to advancing our current returns candidates, expansion into respiratory disease marks our fourth major disease focus, highlighting our commitment to structure a leading pipeline of cannabinoid-based therapies.”

Dr. Sazzad Hossain, Chief Scientific Officer, stated, “Current treatments for COPD are complication and ineffective and there is publicly no cure available. It is well known that cannabinoids manifest bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapy may offer safer and in addition effective treatment options for COPD.”

InMed researcher, Dr. Dmitri Pechkovsky, enjoin conduct the initial discovery work in the laboratory of Dr. Pascal Bernatchez at the University of British Columbia. Dr. Pechkovsky has extended research experience in pulmonary disorders, specifically, COPD, idiopathic pulmonic fibrosis, and asthma. He earned his Ph.D. in Immunology and Allergy from Minsk State Medical Institute in Belarus and conducted postman-doctoral training at the Research Center Borstel-Leibniz Center with regard to Medicine and Biosciences (FZB), Luebeck University, and University of Freiburg in Germany.

About COPD

Chronic obstructive pulmonary disease (COPD) is a chronic illness of the lower respiratory tract in the lungs that makes it progressively other difficult to breathe. Currently, over 50 the masses people globally have been diagnosed with COPD. However, studies estimate the substantial prevalence of COPD is twice that aggregate. According to the Centers for Disease Control and Prevention (CDC), COPD is the third part leading cause of death in the United States.

The disorder typically develops as a result of inhalation of air pollutants including cigarette emptiness, air pollution, chemical fumes, and dust. Those who pocket from COPD show symptoms including brevity of breath, increased production of pituite, coughing, and chest tightness, caused through the restricted airflow through airways in the lungs. Currently, there is no definitive cure for COPD, limit a variety of treatments do be alive.

About Cannabinoid-based Therapy for COPD

Recent studies bear indicated that cannabinoid-based therapy may have existence effective in ameliorating major symptoms of COPD. THC, the greater active ingredient in cannabis, has been shown to display bronchodilation for up to two hours later administration. To counteract the heightened COPD-induced immune rejoinder in the lungs, THC mobilizes myeloid-derived suppressor cells (MDSCs), a assemblage of white blood cells, which repress T-cell proliferation and activation. Cannabinoids besides exhibit anti-inflammatory effects through the inhibition of cyclooxygenases COX-1 and COX-2, enzymes that afford inflammatory compounds.

About InMed

InMed Pharmaceuticals is a publicly-traded clinical-platform biopharmaceutical company specializing in developing therapies end research and development into the extensive pharmacology of cannabinoids coupled with innovative physic delivery systems. InMed’s development pipeline includes product candidates for glaucoma, arthritis, and epidermoylsis bullosa (EBS), like well as active discovery programs in orofacial aggrieve, ocular allergies, and chronic obstructive pulmonary disease (COPD). InMed’s proprietary Intelligent Cannabinoid Drug Design Platform (IDP), therapeutic product pipeline, and accelerated development way are the fundamental value drivers of the Company.


InMed Pharmaceuticals Inc.

Craig Schneider, President and Chief Executive Officer

Forward Looking Statements

This advice release may contain forward-looking statements and denunciation based on current expectations. These statements should not subsist read as guarantees of future representation or results. Such statements involve known and renownless risks, uncertainties and other factors that may efficient ~ actual results, performance or achievements to subsist materially different from those implied ~ dint of. such statements. Although such statements are based steady management’s reasonable assumptions, there be possible to be no assurance that such assumptions inclination prove to be correct. We assume ~t one responsibility to update or revise them to contemplate new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, work or achievements to be materially various from any future results, performance or achievements expressed or implied ~ dint of. the forward-looking information contained in this.

All forward-looking information herein is adapted in its entirety by this cautionary recital, and InMed Pharmaceuticals disclaims any engagement to revise or update any of that kind forward-looking information or to publicly advertise the result of any revisions to ~ one of the forward-looking information contained in this to reflect future results, events or developments, do not include as required by law.

These risks and uncertainties hold, among others, the possibility that clinical trials command not be successful, or be completed, or corroborate earlier clinical trial results, risks associated through obtaining funding from third parties, risks connected to the timing and costs of clinical trials and the reception of regulatory approvals


Copyright © 2009 Marketwired. All rights incommunicative. All the news releases provided through Marketwired are copyrighted. Any forms of copying other than every individual user’s personal reference exclusively of express written permission is prohibited. Further assignment of these materials is strictly forbidden, including mete not limited to, posting, emailing, faxing, archiving in a persons database, redistributing via a computer reticulated or in a printed form.

Latest Stories

By Elizabeth White

“Ulunsoft is a sudden motion-up that focuses on how enterprises raise cloud-based IT infrastructure for dealing,” explained Haibo Zhu, President of Ulunsoft Corp, in this parley at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 06:15 AM EDT  Reads: 2,414

By Pat Romanski

The 5th International DevOps Summit, co-located by 17th International Cloud Expo – root held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call conducive to Papers is open. Born out of proven lucky hit in agile development, cloud computing, and operation automation, DevOps is a macro inclination you cannot afford to miss. From showcase result stories from early adopters and structure-scale businesses, DevOps is expanding to organizations of quite sizes, including the…

Jun. 3, 2015 06:15 AM EDT  Reads: 4,321

By Elizabeth White

“There is a unregenerate synchronization between the business models, the IoT is in that place to support ,” explained Brendan O’Brien, Co-fail and Chief Architect of Aria Systems, in this interview at the 15th International Cloud Expo®, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 06:00 AM EDT  Reads: 6,417

By Elizabeth White

The 17th International Cloud Expo has announced that its Call towards Papers is open. 17th International Cloud Expo, to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, brings side by side Cloud Computing, APM, APIs, Microservices, Security, Big Data, Internet of Things, DevOps and WebRTC to undivided location. With cloud computing driving a higher percentage of endeavor IT budgets every year, it becomes increasingly grave to plant your flag in this fortified-expanding bu…

Jun. 3, 2015 05:30 AM EDT  Reads: 4,456

By Elizabeth White

The 4th International Internet of @ThingsExpo, co-located by the 17th International Cloud Expo – to subsist held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call conducive to Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web further than 20 years ago.

Jun. 3, 2015 05:30 AM EDT  Reads: 2,036

By Elizabeth White

“SOASTA built the universal of cloud testing in 2008. It’s grown from moderately meager beginnings to where now we are provisioning hundreds of thousands of servers adhering a daily basis on behalf of customers around the world to test their applications,” explained Tom Lounibos, CEO of SOASTA, in this parley at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 05:00 AM EDT  Reads: 4,493

By Liz McMillan

SYS-CON Events announced today that SUSE, a pioneer in be severed source software, will exhibit at SYS-CON’s DevOps Summit 2015 New York, that will take place June 9-11, 2015, at the Javits Center in New York City, NY. SUSE provides trusty, interoperable Linux, cloud infrastructure and storage solutions that bestow enterprises greater control and flexibility. More than 20 years of engineering superiority, exceptional service and an unrivaled member of a ~ship ecosystem power the products and patronage that help …

Jun. 3, 2015 04:00 AM EDT  Reads: 1,271

By Pat Romanski

The basic integration science, as defined by ESBs, hasn’t changed because more than a decade. Most blur integration providers still rely on one ESB architecture and their proprietary connectors. As a determination, enterprise integration projects suffer from constraints of availability and reliableness of these connectors that are not re-usable thwart other integration vendors. However, the quick adoption of APIs and almost universally present availability of APIs amongst most SaaS and Cloud applications are ra…

Jun. 3, 2015 04:00 AM EDT  Reads: 826

By Elizabeth White

“We be under the necessity developers who are really passionate touching getting their code out to customers, ~t any matter what, in the shortest potential time. Operations are very focused forward procedures and policies,” explained Stan Klimoff, CTO of Qubell, in this meeting at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 04:00 AM EDT  Reads: 5,050

By Liz McMillan

With greater technology companies and startups seriously embracing IoT strategies, at that time is the perfect time to be present at @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as “IoT-Ready” being of the kind which it can be! Internet of @ThingsExpo, distress place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located by 17th Cloud Expo and will lineament technical sessions from a rock luminary conference faculty and the leading in…

Jun. 3, 2015 04:00 AM EDT  Reads: 2,739

By Carmen Gonzalez

DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located through 17th Cloud Expo and will aspect technical sessions from a rock doom conference faculty and the leading toil players in the world. The widespread lucky hit of cloud computing is driving the DevOps whirling in enterprise IT. Now as not before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is nay time to wait for long developmen…

Jun. 3, 2015 03:15 AM EDT  Reads: 2,433

By Liz McMillan

“Will Jaya is a cast source for server integration and storage solutions. If you are looking since any specific configurations for a intend we can help you configure based up~ the body your needs and requirements,” explained Netty Goya, CEO of Will Jaya, in this interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 03:15 AM EDT  Reads: 3,592

By Elizabeth White

“SendGrid sends on the eve 15 billion emails a month and action all the events associated with that, round a trillion events a year,” explained Aaron Beach, Senior Data Scientist at SendGrid, in this conference at Cloud Expo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 03:00 AM EDT  Reads: 865

By Carmen Gonzalez

Health care systems from one side of to the other the globe are under enormous turn, as facilities reach capacity and costs endure to rise. M2M and the Internet of Things own the potential to transform the assiduity through connected health solutions that can make care more efficient while reducing costs. In actuality, Vodafone’s annual M2M Barometer Report forecasts M2M applications boil to 57 percent in health care and life sciences by 2016. Lively is one of Vodafone’s hale condition care partners, whose solutions enable o…

Jun. 3, 2015 02:30 AM EDT  Reads: 2,983

By Pat Romanski

“Connect2Me is basically a courageous changer in the IoT industry. We hold created IoT connecter middleware that have power to enable a connection to any ~ly of device,” explained Yasser Khan, CTO of Connect2Me, in this parley at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Jun. 3, 2015 02:15 AM EDT  Reads: 3,141


So , granting that you take methimazole with the employment of amitriptyline continous, chances are that you be possible to develop white blood cells.

Both comments and pings are currently closed.